Objectives: Hypertension is a risk factor for the development of cardiovascular and kidney disease, but treatment can substantially reduce risks. Many patients avoid antihypertensive medications because of fear of sideeffects. Although associations between antihypertensives and sexual dysfunction in men have been documented, it remains unclear whether antihypertensives are associated with sexual dysfunction in women. We conducted a cross-sectional analysis of baseline data from women in the Systolic Blood Pressure Intervention Trial (SPRINT) to evaluate the relations among class of antihypertensive medication and the outcomes: sexual activity and sexual function.
INTRODUCTION
H ypertension is an important risk factor for the development of cardiovascular disease [1] , the leading cause of death in the United States [2] . Additionally, hypertension is associated with stroke [3] and kidney failure [4, 5] . Adequate treatment of hypertension can result in substantial reductions in morbidity and mortality; however, many patients avoid antihypertensive medications because of the fear of side-effects. In total, 70% of patients with hypertension who experience side-effects are nonadherent with medications [6] and individuals whose antihypertensive agents have an adverse effect on quality of life (QoL) have 40-60% higher rates of discontinuation than those who are not affected [7] .
One important aspect of QoL that may be affected by antihypertensive medications is sexual function. Although several studies have documented associations among certain antihypertensive medications -particularly b-blockers [8, 9] and diuretics [10] [11] [12] [13] [14] -with sexual dysfunction in men, it is unclear whether antihypertensive medications are associated with sexual dysfunction in women. The issue is complicated by the fact that hypertension itself is associated with female sexual dysfunction [15] [16] [17] [18] , and hypertension often develops in tandem with other factors that may influence female sexual function such as aging, menopause, and medical comorbidities. Additionally, female sexual function is a complex phenomenon, influenced by numerous biologic and psychosocial factors.
There are biologically plausible pathways by which antihypertensive medications may affect female sexual function. Many antihypertensive agents act by relaxing the smooth muscle of the tunica media resulting in vasodilation; the increased blood flow to vaginal tissues during arousal is also because of relaxation of smooth muscle [19] . Animal models have shown that nitric oxide is involved in female sexual arousal [19] ; several antihypertensive medications -b-blockers [20, 21] , angiotensin-converting enzyme inhibitors (ACEIs) [22, 23] , angiotensin receptor blockers (ARBs) [22, 24] , and calcium channel blockers (CCBs) [25] -affect the nitric oxide pathway, and may therefore actually improve female sexual function. In contrast, b-blockers have been found to decrease serum testosterone levels [26] [27] [28] in men; their effects on serum testosterone in women are unknown. Serum testosterone has been associated with female sexual dysfunction in some studies [29] [30] [31] [32] [33] [34] , although this remains an area of controversy [35] . If b-blockers also lower testosterone in women, they may have negative effects on female sexual function.
Our aim was to conduct a cross-sectional evaluation of the associations among different classes of antihypertensive medications and sexual activity and sexual function among female participants in the Systolic Blood Pressure Intervention Trial (SPRINT). We hypothesized a priori that b-adrenergic blockers would be correlated with poorer sexual function in women, given their potential effects on sexual function in men and based on prior studies [7, 9] , whereas other classes of antihypertensive medications would not.
METHODS

Participants
SPRINT is a multicenter randomized controlled trial to test the effects of different blood pressure (BP) control targets (<140 mmHg vs. <120 mmHg) on a variety of outcomes, including cardiovascular events, kidney function, and cognitive function. SPRINT recruited participants aged 50 years and older (including persons with cardiovascular disease, chronic kidney disease (CKD), age at least 75 years, or a 10-year Framingham cardiovascular risk of !15%). Persons with higher than 1 g/day proteinuria, diabetes mellitus, polycystic kidney disease, or a history of stroke were excluded. Full details on the design of SPRINT, including definitions for inclusion and exclusion criteria, have been previously published [36, 37] . Baseline data were collected in 2010-2013. A random sample of participants (1987/9361, 21.2%) completed questionnaires regarding QoL. Women in the QoL subset are the basis for this analysis. All participants provided signed informed consent. The study was approved by the Institutional Review Board at each study site and was registered with clinicaltrials.gov (NCT01206062).
Primary measures
Sexual activity included any activity with or without a partner in the prior 4 weeks. Sexual function was assessed using the Female Sexual Function Index (FSFI) [38] , a highly validated 19-item questionnaire that assesses sexual function over six domains: desire, arousal, lubrication, orgasm, pain, and satisfaction. Higher scores indicate better sexual function, and a score of less than 27 has been established as a cutoff for sexual dysfunction [39] .
Antihypertensive class was defined by the medications participants were taking at the baseline visit prior to randomization. Some participants were taking multiple and some were taking no antihypertensive medications. In addition to counting the number of medications used by each participant, we created indicator variables to capture use of any antihypertensive medication, use of ACEI or ARB, use of diuretics, use of b-blockers, use of CCBs, and the use of any other antihypertensive agents (a-blockers, a, b-blockers, direct vasodilators, direct renin inhibitors, or central a-2 agonists and other centrally acting drugs). Each medication class was considered as a dichotomous variable. Classifications were not mutually exclusive for women who were on more than one antihypertensive medication.
Covariates
All covariates were selected a priori based on factors related to sexual function in prior literature. Covariates included BP, demographic variables (age, race, and ethnicity, education level, living situation), other medications which may affect sexual function [selective serotonin reuptake inhibitors (SSRIs) or hormone therapy], and the presence of certain comorbidities (CKD, hyperlipidemia, and cardiovascular disease).
BP measurements were the average of three measurements taken at 1-min intervals after the participant had been sitting quietly in a room for 5 min. SPRINT did not assess whether participants were in a romantic relationship, but participants did indicate whether they lived with others or alone. Use of SSRIs or hormone therapy was assessed by self-report. Presence of CKD was defined as an estimated glomerular filtration rate of 20-59 ml/min per 1.73 m 2 . Hyperlipidemia was defined by serum total cholesterol higher than 200 mg/dl. Cardiovascular disease was defined by previous clinical or subclinical cardiovascular disease other than stroke (individuals with stroke were excluded from SPRINT).
Analysis
Categorical variables are reported as N (%) and continuous variables as mean (SD). Total and domain-specific FSFI scores were calculated only for sexually active women, with missing responses replaced with mean imputation [40] .
Sexual activity
Among women in the QoL sample, we constructed separate univariable logistic regression models to examine the relation between any (vs. no) antihypertensive medication use and sexual activity; and class of antihypertensive medication and sexual activity. Multivariable models were constructed to examine the relations among the same independent variables and the outcome while adjusting for above covariates. We report odds ratios (OR) and 95% confidence intervals.
Sexual function
Among sexually active women in the QoL sample, we fit separate univariable linear regression models to examine the correlation between any antihypertensive medication at baseline (vs. no antihypertensive medication) and sexual function; and class of antihypertensive medication and sexual function. Multivariable models were constructed to examine the relations among the same independent variables and the outcome while adjusting for above covariates. Results are reported as b coefficients and 95% confidence intervals.
Standard regression diagnostics were used to evaluate assumptions for both logistic and linear models, and no important violations were found. As sensitivity analyses, we also fit multivariable logistic and multivariable linear models where the dichotomous variable for any antihypertensive medication use was replaced by the number of medication classes used (0-4). We considered two-tailed P < 0.05 statistically significant. In these analyses, we did not adjust for multiple comparisons. All analyses were conducted with SAS 9.4 (Cary, North Carolina, USA).
RESULTS
Of the 3332 randomized women in SPRINT, 1102 (33%) were on a b-blocker, 1173 (35%) were on a CCB, 1723 (52%) were on a diuretic, 1902 (57%) were on an ACEI/ARB, and 255 (8%) were on another antihypertensive medication. There were 690 women in the QoL subset of SPRINT. Of these, 183 (26.5%) were sexually active, 452 (65.5%) were not, and 55 (8.0%) had missing data regarding sexual function ( Fig. 1 ). All women in the QoL subset were included in the analysis of sexual activity. Only sexually active women were included in the analysis of sexual function. Demographic characteristics are summarized in Table 1 . In the QoL subset, mean age was 67.6 (SD 10) years and 43.6% were white. The median number of medications used by sexually active women was 2. In total, 61% of sexually active women in the QoL subset were taking more than one category of antihyperten-sive medication. The most common combinations were a diuretic with an ACEI or ARB (18.6%), a b-blocker with a diuretic and an ACEI or ARB (7.1%), and a CCB with a diuretic and an ACEI or ARB (7.1%).
Sexual activity
Results of multivariable models with sexual activity as the dependent variable are presented in Table 2 . For the model incorporating use of 'any antihypertensive medication' (model 1), younger women (P < 0.001), more highly educated women (P ¼ 0.002), and those living with others (P ¼ 0.018) had higher odds of being sexually active. Odds of sexual activity differed among race/ethnic groups (P ¼ 0.003), with white, black, and Hispanic women having lower odds than women of other races (including multiracial women); however, there were only 10 women in this group, so these results should be interpreted with caution. Similar results were observed for the model incorporating use of specific antihypertensive medication classes. Prevalence of sexual activity did not differ for women on any antihypertensive medication(s) vs. women on no antihypertensive medication (P ¼ 0.81, model 1).
However, in the model examining 'specific antihypertensive classes' (model 2), women taking an ACEI or ARB had increased odds of sexual activity compared to women not taking these medications [OR 1.66 (1.12, 2.47), P ¼ 0.011]. No other class of antihypertensive medication was significantly associated with sexual activity. In sensitivity analyses, number of antihypertensive classes used was not significantly related to sexual activity (P ¼ 0.99).
Sexual function
Among sexually active women, the mean FSFI score was 25.3 (SD 6) ( Table 3) . Ninety-six (52.5%) sexually active women were below the cutoff for sexual dysfunction. FSFI domain scores were similar for women taking different classes of antihypertensive medications. In univariable analyses, no class of medication was significantly associated with FSFI score (results not shown). Using the sample SD (6.0), these analyses had 82% (85, 92, and 90%) power to detect a difference of three units in FSFI scores between b-blocker (CCB, diuretic, and ACEI/ARB, respectively) users and nonusers.
In multivariable analyses, there is a trend toward better sexual function among women on no antihypertensive agents that did not reach statistical significance [b 2.73 (À0.22, 5.68), P ¼ 0.069], (model 1, Table 4 ). There were no significant associations found between any class of antihypertensive medication and sexual function (model 2, Table 4 ). After controlling for specific classes of antihypertensive medications, hormone therapy use was associated with poorer sexual function scores [b À3.42 (À6.74, À0.10), P ¼ 0.044]. In sensitivity analyses, the number of antihypertensive medications used was not significantly related to sexual function (P ¼ 0.85).
DISCUSSION
In this cross-sectional analysis of sexually active women 50 years and older at high risk for cardiovascular disease, we found that approximately one-quarter of women were sexually active, and of these, over half were classified as having sexual dysfunction. Women taking ACEI/ARBs were more likely to be sexually active compared to women not on these medications. No single class of antihypertensive medication was correlated with sexual function.
Other authors have found similar prevalence of sexual activity among older women with medical problems [41] . In caring for these women, providers should be aware that some are still sexually active. It could be hypothesized that some of these women became sexually inactive because of sexual dysfunction; however, one prior study found that older women with poor sexual function are just as likely to remain sexually active as those with better sexual function [42] . The prevalence of sexual dysfunction was high in this sample; other studies using the FSFI in older women have also found similar results [42] [43] [44] . There are associations among medical comorbidities such as cardiovascular disease [45] , CKD [46, 47] , and hypertension [48] with sexual dysfunction. The combination of older age and medical comorbidities may explain the high prevalence of sexual dysfunction in our sample.
Women in SPRINT who were taking an ACEI or ARB at baseline were more likely to be sexually active than women not taking these medications, even when adjusting for other factors that may affect sexual function. The mechanism through which ACEI/ARBs may affect sexual function is not clear. In animal models, inhibition of nitric oxide synthase has been shown to reduce smooth muscle relaxation in clitoral tissue [49] , and phosphodiesterase-5 inhibitors, which promote nitric oxide accumulation, have been shown to enhance stimulation-induced clitoral blood flow [50] . ACEIs and ARBs decrease the breakdown of bradykinin, which enhances the accumulation of nitric oxide in the Each estimate is adjusted for all other variables with estimates shown; in model 2, results for each class of antihypertensive use are adjusted for use of other classes of antihypertensives. ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; CKD, chronic kidney disease; SSRI, selective serotonin reuptake inhibitor. a Female Sexual Function Index -higher scores indicate better sexual function. endothelium [22] ; increased nitric oxide may lead to increased clitoral bloodflow and improved arousal. Another mechanism may be through QoL; ACEIs and ARBs are associated with better QoL scores [7, 51] , and higher QoL is associated with being sexually active [52, 53] . Although we did control for education as a proxy for socioeconomic status, there still may be socioeconomic differences among women who take ACEI/ARBs and women who do not, and socioeconomic status may be related to whether women are sexually active [54] . Additionally, younger patients may be more likely to receive ACEI/ARBs, and younger patients are more likely to be sexually active. Although we did adjust for age in our analyses, there is the possibility for residual confounding. Finally, there is the possibility that this association is spurious, and our findings should be confirmed in future studies.
No single class of antihypertensive medication in SPRINT was associated with sexual function. Prior studies of the effects of antihypertensive medications on female sexual function have yielded mixed results. One study found that b-blockers have an adverse effect [9] , whereas three studies did not [11, 55, 56] . Two studies found that CCBs are not associated with female sexual function [13, 55] , and one study found no association between a-blockers, ACEIs, or thiazides and sexual function [55] . A more recent study found no associations between CCBs, b-blockers, ACEI/ ARBs, diuretics, or a-blockers and female sexual dysfunction [57] . However, many of these studies are small, and none use a validated measure of sexual function.
Two studies did assess sexual function more comprehensively. In one study, 120 postmenopausal women were randomized to valsartan or atenolol and sexual function was assessed with a 10-item questionnaire [58] . These authors found that b-blockers had adverse effects and ARBs had positive effects on sexual function. In the other study, 160 women aged 18-60 with hypertension were randomized to felodipine þ irbesartan or felodipine þ metoprolol and sexual function was assessed with the FSFI [59] . In women placed on irbesartan, FSFI scores improved, whereas in women placed on metoprolol, there were no changes in FSFI scores. The mean improvement in FSFI scores for women on irbesartan was by less than 1 point, so the clinical significance is questionable.
Many women in SPRINT were taking multiple antihypertensive medications, which may make it more difficult to isolate the effects of any one class of medication; however, we did control for other classes of medications in our multivariable analyses. The numbers of women on monotherapy for each class were too small to include them in multivariable analyses. However, the unadjusted mean FSFI total and domain scores appear comparable for women on monotherapy and women on multiple medications (Supplemental table, http://links.lww.com/HJH/A601).
Our study has several strengths. It used a well validated, multidimensional assessment of female sexual function. We also controlled for a number of important potential confounders that have not been assessed in prior studies. SPRINT also gave us the opportunity to assess every major class of antihypertensive medication, as opposed to only one or two medications, in the same study. Finally, this study gave us important information about sexual activity and sexual function in an older cohort of women who are often excluded from studies on sexual function.
There are several limitations to this study. First, the sample size is moderate. However, our study had greater than 80% power to detect differences of at least three units in FSFI scores for each antihypertensive medication class. Although larger studies may be able to detect smaller differences, these differences are not likely to be clinically significant. In addition, there were only 19 women not taking any antihypertensive medications, so results among this group should be interpreted with caution. Second, our data are cross-sectional. Longitudinal studies that evaluate changes in sexual function with different antihypertensive agents could yield more clinically useful information. For example, women may have previously discontinued a particular antihypertensive medication because of sexual side-effects. SPRINT is a 6-year study, so we will have the opportunity to follow these women over time.
Some older women with medical comorbidities are sexually active, but prevalence of sexual dysfunction in this group is high. Women taking an ACEI/ARB may be more likely to be sexually active, but cause and effect cannot be determined in these analyses. These results should be confirmed in subsequent longitudinal studies. No single class of antihypertensive medication was associated with sexual dysfunction. These results should be confirmed in longitudinal analyses, but based on the power estimates of this study; it appears that antihypertensive medications are unlikely to affect sexual function.
ACKNOWLEDGEMENTS
The manuscript has not been published and is not being considered for publication elsewhere, in whole or in part, in any language, except as an abstract. We presented an abstract of this data as poster at the Society of General Internal Medicine national conference in San Diego, California in April 2014. The SPRINT is funded with Federal funds from the NIH, including the National Heart, Lung, and Blood Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Aging, and the National Institute of Neurological Disorders and Stroke, under contract numbers HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN26820 0900048C, HHSN268200900049C, and Inter-Agency Agreement Number A-HL-13-002-001. It was also supported in part with resources and use of facilities through the Department of Veterans Affairs. The SPRINT investigators acknowledge the contribution of study medications (azilsartan and azilsartan combined with chlorthalidone) from Takeda Pharmaceuticals Inc. H.N.T. is supported by a grant from the Agency on Healthcare Research and Quality (AHRQ) (5K12HS022989). S.P.G. is partially supported by a grant from AMGEN. No other author has any conflicts of interest to report. All components of the SPRINT study protocol were designed and implemented by the investigators. The investigative team collected, analyzed, and interpreted the data. All aspects of manuscript writing and revision were carried out by the coauthors. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, the US Department of Veterans Affairs, or the United States Government. For a full list of contributors to SPRINT, please see the supplementary acknowledgement list: ClinicalTrials.gov Identifier: NCT01206062. We also acknowledge the support from the following CTSAs funded by NCATS: CWRU: UL1TR000439, OSU: UL1RR025755, U Penn: UL1RR0241 34& UL1TR000003, Boston: UL1RR025771, Stanford: UL1TR000093, Tufts: UL1RR025752, UL1TR000073 & UL1TR001064, University of Illinois: UL1TR000050, University of Pittsburgh: UL1TR000005, UT Southwestern: 9U54TR000017-06, University of Utah: UL1TR000105-05, Vanderbilt University: UL1 TR000445, George Washington University: UL1TR000075, University of CA, Davis: UL1 TR000002, University of Florida: UL1 TR000064, University of Michigan: UL1TR000433, Tulane University: P30GM 103337 COBRE Award NIGMS.
